Advertisement

Topics

Gossamer Bio, Inc. Company Profile

14:57 EDT 15th October 2018 | BioPortfolio

Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.


News Articles [27 Associated News Articles listed on BioPortfolio]

BMS Veteran Luisa Salter-Sid Named Gossamer Chief Scientific Officer

Luisa Salter-Cid has joined Gossamer Bio as the San Diego company’s chief scientific officer. Salter-Cid comes to Gossamer from Bristol-Myers Squibb (NYSE: BMY), where she held various positions ove...

Gossamer’s war chest

Gossamer has raised $330 million this year to back its growing pipeline and winning management team from Receptos.

Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924

Aerpio Pharmaceuticals (OTCQB:ARPO), announced an exclusive global license agreement with a wholly owned subsidiary of Gossamer Bio, GB004, for the development and commercialization of Aerpio’s HIF-...

Startup Gossamer Bio Snags $230 Million in Funding, Names New CEO

Since it first launched with $100 million in the bank earlier this year, Gossamer Bio has been on something of a roll.

Gossamer to decide lead autoimmune candidate strategy by end of 2018

Gossamer Bio is making plans for an upcoming autoimmune trial in 2019 following its recent $230m Series B raise, said...Read More... The post Gossamer to decide lead autoimmune candidate strategy by e...

Gossamer launched with $100mm in Series A funding

Former Receptos executives have launched and will take leadership positions at Gossamer Bio Inc.

Gossamer Bio secures $230m to support growth and expansion

US-based biotechnology company Gossamer Bio has raised $230m in a series B financing round to support its growth and pipeline...Read More... The post Gossamer Bio secures $230m to support growth and e...

Gossamer Bio closes $230mm Series B round

Gossamer Bio Inc. raised $230mm through its Series B round led by Hillhouse Capital. New buyers Invus, a subsidiary of the Abu Dhabi Investment Authority, the Baupost Group, and Polaris Partners were ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Gossamer Bio, Inc.

Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various ta...

Gossamer Bio Inc.

Gossamer Bio is a San Diego-based biopharmaceutical company focused on discovering, developing, and commercializing immunology-based therapeutics in the autoimmune, allergy/inflam...

More Information about "Gossamer Bio, Inc." on BioPortfolio

We have published hundreds of Gossamer Bio, Inc. news stories on BioPortfolio along with dozens of Gossamer Bio, Inc. Clinical Trials and PubMed Articles about Gossamer Bio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Gossamer Bio, Inc. Companies in our database. You can also find out about relevant Gossamer Bio, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record